A Prospective Observational Study on the Efficacy of detecting circulating tumor DNA by Means of a Next-Generation Sequencer Using Cell-Free DNA in lung cancer patients

A Prospective Observational Study on the Efficacy of detecting circulating tumor DNA by Means of a Next-Generation Sequencer Using Cell-Free DNA in lung cancer patients - cfDNA analysis in lung cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041237

Enrollment

Registered

2020-07-28

Start date

2020-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Non-small cell lung cancer patients clinical stage IB-IVA. 2. 20 years old or above 3. With written informed consent.

Exclusion criteria

Exclusion criteria: 1. Positive for infection (HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody) 2. Cases in which the principal investigator determined that the subject was inappropriate

Design outcomes

Primary

Measure	Time frame
The purpose of this research is to verify the effectiveness of detecting circulating tumor DNA analysis by means of a next-generation sequencer using cell free DNA (cfDNA) derived from lung cancer patients and to verify the relation to the postoperative recurrence.	—

Countries

Japan

Contacts

Public ContactKazuhisa Tanaka

Graduate School of Medicine,Chiba University Department of General Thoracic Surgery

kaztanaka-ths@umin.ac.jp043-222-7171

Outcome results